Compounded Aseptic Medicines

Description

This Framework Agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland. Lot 1: Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Atezolizumab Cetuximab Doxorubicin Epirubicin Infliximab (Inflectra®), (Remicade®), (Remsima®) Nivolumab Pembrolizumab Pertuzumab The Authority intends to awarded all presentations within this Lot to a single supplier. Lot 2: Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Cyclophosphamide Fluorouracil Irinotecan Methotrexate Rituximab (Mabthera®), (Rixathon®), (Truxima®) The Authority intends to awarded all presentations within this Lot to a single supplier. Lot 3: Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Bortezomib Carboplatin Cisplatin Docetaxel Gemcitabine Oxaliplatin Trastuzumab (Herceptin®), (Herzuma®) Vincristine The Authority intends to awarded all presentations within this Lot to a single supplier. Lot 4: Compounded Aseptic Medicines - All Other Presentations upply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, The molecules included in this Lot are, Bevacizumab Cytarabine Infliximab (Zessly®) Insulin Methotrexate Natalizumab Nivolumab Paclitaxel Pemetrexed Tocilizumab Trastuzumab (Kanjinti®), (Ontruzant®) Trastuzumab Subcutaneous Vedolizumab Each product line will be treated as an individual Lot and awarded as an unranked multi-supplier framework.